Jan. 3, 2008 -Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its xTAG(TM) Respiratory Viral Panel (RVP). xTAG RVP is the first FDA-cleared assay to simultaneously detect and identify 12 viruses and viral subtypes that together are responsible for more than 85 percent of respiratory viral infections... Luminex' Press Release -
Blog Archive
-
▼
2008
(297)
-
▼
January
(16)
- Transgene's Therapeutic Vaccine TG4010, Phase IIb ...
- Agennix, Pivotal Trial of Talactoferrin Alfa in Fi...
- Peregrine Pharmaceuticals, Approval to Conduct a P...
- Vapotherm, Patent For Apparatus And Method For Res...
- Serenex, to Evaluate Proprietary Small Molecule Hs...
- Kamada, Phase I Studies with Aerosolized AAT for t...
- 20/20 GeneSystems, Licenses Lung Cancer Blood Test...
- PhytoMedical, Patented Anti-Cancer Compounds Kill ...
- Pharmaxis, Aridol, first Asian Approval
- Nycomed, ALVESCO , FDA approval for the U.S. market
- Aeras and Crucell, Start of a Tuberculosis Vaccine...
- Exelixis, Phase 1/2 Trial of XL184 in Patients Wit...
- Genzyme, License Agreement with Moffitt Cancer Cen...
- Luminex , FDA Clearance for xTAG Respiratory Viral...
- GlaxoSmithKline and Theravance, 642444 and 685698...
- Alnylam, Progress in Clinical Development of ALN-R...
-
▼
January
(16)